Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Opdivo-Yervoy nivolumab-ipilimumab Malignant Pleural Mesothelioma (MPM) Reimburse with clinical criteria and/or conditions Complete
Opdualag nivolumab and relatlimab unresectable or metastatic melanoma Reimburse with clinical criteria and/or conditions Complete
Opsumit Macitentan Pulmonary arterial hypertension List with clinical criteria and/or conditions Complete
Opsynvi macitentan and tadalafil Pulmonary arterial hypertension Reimburse with clinical criteria and/or conditions Complete
Opzelura ruxolitinib atopic dermatitis Active
Opzelura ruxolitinib Nonsegmental vitiligo Received
Oralair Grass Pollen Allergen Extract Allergic rhinitis List with criteria/condition Complete
Orencia Abatacept Arthritis, Rheumatoid List in a similar manner Complete
Orencia Abatacept Arthritis, Rheumatoid List with clinical criteria and/or conditions Complete
Orencia Abatacept Arthritis, Juvenile Idiopathic & Juvenile Rheumatoid List with clinical criteria and/or conditions Complete